Table 1.
Patient characteristics at the time of [68Ga]Ga-PSMA-11 scan
| Patient # | Age | Sex | Thyro-globulin (ng/mL); Ab +/− | TSH (mIU/ L) | Tumor type | Years since diagnosis | Treatment history | Years Since RAI; EBRT | I-123/131 uptake on most recent scan? | Months to PSMA PET |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 78 | M | 17; − | 0.36 | PTC | 14 | S, RAIx1, EBRT | 6; 1 | No | 3.0 |
| 2 | 58 | F | 520.2; + | 0.01 | HCC | 5 | S, RAIx2, EBRT | 3; 1 | No | 1.8 |
| 3 | 80 | M | 22.0; − | 0.11 | PDPTC | 28 | S | n/a; n/a | No | 2.4 |
| 4 | 79 | M | 245.1; + | 2.7 | ATC | < 1 | S | n/a; n/a | Unknown | 0.4 |
| 5 | 72 | F | 1771.0; − | n/a | FTC | 5 | S, RAIx2 | 4; n/a | No | 1.8 |
| 6 | 65 | F | 2125.8;− | 0.01 | PDPTC | 3 | S, EBRT | n/a; 1 | No | 3.0 |
| 7 | 66 | F | 7.3; − | 0.11 | PTC | 3 | S, RAIx1, EBRT | 3; 3 | No | 5.3 |
| 8 | 46 | F | 0.1; − | 12.1 | ATC | < 1 | S, RAIx1 | 0.5; n/a | No | 1.2 |
| 9 | 62 | M | 0.1; + | 0.37 | PTC | 2 | S, RAIx2 | 1; n/a | No | 0.7 |
| 10 | 47 | F | 20,540.0; − | 0.01 | FTC | < 1 | S | n/a; n/a | Yes* | 11.4 |
| 11 | 54 | M | 15.6; − | 0.13 | HCC | 8 | S, RAIx3, EBRT | 4; 2 | Unknown | 1.5 |
Time to PSMA PET: months from most recent 2-[18F]FDG PET or [123I]Iodide/[131I]Iodide scan to [68Ga]Ga-PSMA-11 PET
Ab anti-thyroglobulin antibodies, TSH thyroid stimulating hormone, PTC papillary thyroid carcinoma, HCC Hurthle cell carcinoma, PDPTC poorly differentiated papillary thyroid carcinoma, ATC anaplastic thyroid carcinoma, FTC follicular thyroid carcinoma, S surgery, RAI radioactive iodine therapy, EBRT external beam radiation therapy, Chemo chemotherapy
*Patient 10 was planned for RAI which was performed approximately 1 month after imaging workup (including PSMA PET)